Autoimmune disease, cardiovascular diseases, Systemic lupus erythematosus, rheumatoid arthritis, cardiovascular riskEnfermedad autoinmune, enfermedades cardiovasculares, lupus eritematoso sistemico, artritis reumatoide, riesgo cardiovascular

1. Hammer GD, McPhee SJ, editores. Fisiopatología de la enfermedad. 8.ª ed. Ciudad de México: McGraw Hill; 2019.
2. Nguyen P, Baerwald C. Rheuma, Entzündung und kardiovaskuläres Risiko [Rheumatic diseases, inflammation and cardiovascular risk]. Dtsch Med Wochenschr. 2021 Apr;146(7):474-477. German.
3. Hedar AM, Stradner MH, Roessler A, Goswami N. Autoimmune rheumatic diseases and vascular function: the concept of autoimmune atherosclerosis. J Clin Med. 2021;10(19):4427.
4. Atzeni F, Nucera V, Gerratana E, Fiorenza A, Gianturco L, Corda M, Sarzi-Puttini P. Cardiovascular Consequences of Autoimmune Rheumatic Diseases. Curr Vasc Pharmacol. 2020;18(6):566-579. https://doi.org/10.2174/1570161118666200127142936
5. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, Weyand CM. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000 Jun 27;101(25):2883-8. https://doi.org/10.1161/01.cir.101.25.2883
6. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018 Apr 23;361:k1036.
7. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011 May;63(5):1182-9.
8. Juárez M, Misichia R, Alarcón G. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis-dermatomyositis. Rheum Dis Clin North Am. 2003 Feb;29(1):163-84. https://doi.org/10.1016/s0889-857x(02)00100-x
9. Villa-Forte A, Mandell BF. Trastornos cardiovasculares y enfermedad reumática. Rev Urug Cardiol. 2012;27(3):336.
10. Shoenfeld Y. The heart in rheumatic, autoimmune and inflammatory diseases: pathophysiology, clinical aspects and therapeutic approaches, 1st edition. Isr Med Assoc J [internet]. 2017 Jun;19(6):395-6. Disponible en: https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2017&month=06&page=395
11. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag. 2008;4(3):605-14. https://doi.org/10.2147/vhrm.s2453
12. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010 Nov;15(6):543-62.
13. Isoda K, Kamezawa Y, Tada N, Sato M, Ohsuzu F. Myocardial hypertrophy in transgenic mice overexpressing human interleukin 1alpha. J Card Fail. 2001 Dec;7(4):355-64. https://doi.org/10.1054/jcaf.2001.28221
14. Sarwar Z, Yang XP, Peterson EL, Xu J, Janic B, Rhaleb N, Carretero OA, Rhaleb NE. Profibrotic Role for Interleukin-4 in Cardiac Remodeling and Dysfunction. Hypertension. 2015 Sep;66(3):582-9. https://doi.org/10.1161/HYPERTENSIONAHA.115.05627
15. Ayça B, Sahin I, Kucuk SH, Akin F, Kafadar D, Avşar M, Avci II, Gungor B, Okuyan E, Dinckal MH. Increased transforming growth factor-β levels associated with cardiac adverse events in hypertrophic cardiomyopathy. Clin Cardiol. 2015 Jun;38(6):371-7. https://doi.org/10.1002/clc.22404
16. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135-43.
17. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022 Jun;81(6):768-779. https://doi.org/10.1136/annrheumdis-2021-221733
18. Du T, Pang H, Ding F, Ye Y, Li M, Yang X, et al. Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. Medicine (Baltimore). 2020 Nov 20;99(47):e23184. https://doi.org/10.1097/MD.0000000000023184
19. Romero-Díaz J, Vargas-Vóracková F, Kimura-Hayama E, Cortázar-Benítez LF, Gijón-Mitre R, Criales S, et al. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford). 2012 Jan;51(1):110-9. https://doi.org/10.1093/rheumatology/ker307
20. Guzmán López KN, Camas Acero LG, Espinel Núñez NN, Ojeda Carpio AA. Panorámica sobre la indicación de los antiinflamatorios no esteroideos de uso regular en la práctica clínica reumatológica. Rev Cuba Reumatol. 2017 Abr;19(1).
21. Terán-Estrada L. Riesgo cardiovascular de los Inhibidores selectivos de la ciclooxigenasa. Reumatol Clín. 2008 May;4(3):107-14. Spanish. https://doi.org/10.1016/S1699-258X(08)71813-8
22. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Mar;74(3):480-9. https://doi.org/10.1136/annrheumdis-2014-206624
23. Chen HL, Shen LJ, Hsu PN, Shen CY, Hall SA, Hsiao FY. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018 Jan;45(1):83-89. https://doi.org/10.3899/jrheum.160214.
24. Liu B, Zhang TN, Knight JK, Goodwin JE. The glucocorticoid receptor in cardiovascular health and disease. Cells. 2019 Oct 9;8(10):1227.
25. Cappetta D, Bereshchenko O, Cianflone E, Rossi F, et al. Glucocorticoid-Induced Leucine Zipper (GILZ) in cardiovascular health and disease. Cells. 2021 Aug 21;10(8):2155.
26. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-65.
27. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008 Dec 15;59(12):1690-7. https://doi.org/10.1002/art.24092
28. Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020 Jul;16(7):361-379.
29. Kontzias A, Barkhodari A, Yao Q. Pericarditis in systemic rheumatologic diseases. Curr Cardiol Rep. 2020 Sep 10;22(11):142.
30. Gutiérrez J, Roncancio G. Enfermedades reumatológicas y corazón. En: Manifestaciones cardíacas de la enfermedad sistémica. 2012. p. 1145-54.
31. Villa A, Brian M. Trastornos cardiovasculares y enfermedad reumática. Rev Esp Cardiol. 2011;64:809-17.
32. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011 May;70(5):760-5.
33. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct;44(10):2331-7. https://doi.org/10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i
34. Frieri M, Stampfl H. Systemic lupus erythematosus and atherosclerosis: review of the literature. Autoimmun Rev. 2016 Jan;15(1):16-21.
35. Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol. 2001 Mar 1;87(5):663-6, A11. https://doi.org/10.1016/s0002-9149(00)01453-3
36. Wu GC, Liu HR, Leng RX, Li XP, Li XM, Pan HF, et al. Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2016 Jan;15(1):22-37. https://doi.org/10.1016/j.autrev.2015.10.002
37. Tselios K, Gladman DD, Su J, Urowitz MB. Does renin-angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A case-control study. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1497-504.
38. Shahin AA, Shahin HA, Hamid MA, Amin MA. Cardiac involvement in patients with systemic lupus erythematosus and correlation of valvular lesions with anti-Ro/SS-A and anti-La/SS-B antibody levels. Mod Rheumatol. 2004;14(2):117-22.
39. Palacios, E, Naranjo, F. Observational study: risk factors for cardiac involvement in patients with systemic lupus erythematosus. Rev Ocronos. 2020;3(6):782020.
40. García MA, Alarcón GS, Boggio G, Hachuel L, Marcos AI, Marcos JC, et al.; Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL). Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort. Rheumatology (Oxford). 2014 Aug;53(8):1431-8. https://doi.org/10.1093/rheumatology/keu011
41. Vivero F, González E. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmun Rev. 2016;15(12):1134-40.
42. Barreiro Y, García I, Martín N. Endocarditis de Libman-Sacks e insuficiencia aórtica grave en un paciente con lupus eritematoso sistémico en diálisis peritoneal. Nefrología (Madr.). 2011;31(5):619-21.
43. Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007 Jun;6(6):379-86. https://doi.org/10.1016/j.autrev.2007.01.003
44. Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB. Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies. Lupus. 2018 Jul;27(8):1296-302.
45. Thomas G, Cohen Aubart F, Chiche L, Haroche J, Hié M, Hervier B, et al. Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients. J Rheumatol. 2017 Jan;44(1):24-32. https://doi.org/10.3899/jrheum.160493
46. Bourré-Tessier J, Urowitz MB, Clarke AE, Bernatsky S. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). 2015 Jan;67(1):128-35.
47. Teixeira RA, Borba EF, Bonfá E, Martinelli Filho M. Arrhythmias in systemic lupus erythematosus. Rev Bras Reumatol. 2010 Jan-Feb;50(1):81-9.
48. Nishiyama T, Kondo Y, Tsuboi H, Noma H, Tabuchi D. QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine. Mod Rheumatol. 2021 Nov;31(6):1107-1112..
49. Hooks M, Bart B, Vardeny O, Westanmo A, Adabag S. Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm. 2020 Nov;17(11):1930-1935.
50. Wang J, Qian J, Wang Y, Zhao J, Wang Q, Tian Z, et al. Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis. Lupus. 2017 Nov;26(13):1390-1400. https://doi.org/10.1177/0961203317702255
51. Urowitz MB, Ibáñez D, Su J, Gladman DD. Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol. 2016 May;43(5):875-9.
52. Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016 Apr;15(4):344-53.
53. Hurtado-Torres GF, González-Baranda LL, Abud-Mendoza C. Caquexia reumatológica y otras alteraciones nutricionales en las enfermedades reumatológicas. Reumatol Clín. 2015;11(5):316-21.
54. Davis LA, Cannon GW, Pointer LF, Et al. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis. J Rheumatol. 2013 Jun;40(6):809-17.
55. Sanches Machado d'Almeida K, Ronchi Spillere S, Zuchinali P, Corrêa Souza G. Mediterranean diet and other dietary patterns in primary prevention of heart failure and changes in cardiac function markers: a systematic review. Nutrients. 2018 Jan 10;10(1):58. https://doi.org/10.3390/nu10010058
56. Chehade L, Jaafar ZA, El Masri D, Zmerly H, Kreidieh D, Tannir H, et al. Lifestyle modification in rheumatoid arthritis: dietary and physical activity recommendations based on evidence. Curr Rheumatol Rev. 2019;15(3):209-14. https://doi.org/10.2174/1573397115666190121135940

Vol. 64 Núm. 2 (2023)